OMX:一种新型氧递送生物治疗药物改善绵羊可控性失血性休克模型的结局
研究在2-3周龄绵羊中通过急性失血30分钟内使血容量减少50%建立可控性失血性休克模型,比较 Vehicle(n=16)与 400 mg/kg OMX(n=13)输注15分钟的效果。OMX 是一种源自 H-NOX 蛋白家族的非血红蛋白氧载体,仅向严重缺氧组织释放氧气且不清除血管内一氧化氮。结果显示 OMX 耐受良好,显著改善乳酸和碱缺失趋势及血流动力学指标(P<0.05),中位生存时间延长(4.7 vs 6.0 h,P<0.003),总生存率提高(25% vs 85%,P=0.004)。作者结论认为 OMX 在该模型中耐受良好并改善代谢、血流动力学和生存结局。
要点
- 在绵羊可控性失血性休克模型中,400 mg/kg OMX 静脉输注15分钟使总生存率从 Vehicle 组的25%提高到85%(P=0.004)。
- OMX 组中位生存时间为6.0 h,Vehicle 组为4.7 h(P<0.003)。
- OMX 显著改善乳酸和碱缺失趋势及血流动力学指标(P<0.05)。
- OMX 是一种非血红蛋白氧载体,仅向严重缺氧组织释放氧气,且不 scavenge 血管内一氧化氮。
- OMX 在该绵羊模型中耐受良好。
适用人群与场景
- 2-3周龄绵羊,麻醉、插管并机械通气后,通过急性失血30分钟内使血容量减少50%诱导低血容量性休克。
处置流程与药物剂量
- Vehicle(n=16)或 400 mg/kg OMX(n=13)在15分钟内输注给药。
- 整个6小时研究期间监测血流动力学、动脉血气和实验室指标。
研究设计与关键结果
- 研究类型:大型动物(绵羊)可控性失血性休克模型研究;样本量:Vehicle 组 n=16,OMX 组 n=13。
- 干预与对照:400 mg/kg OMX 静脉输注15分钟 vs Vehicle。
- 主要终点结果:OMX 耐受良好,显著改善乳酸和碱缺失趋势及血流动力学指标(P<0.05)。
- 生存结果:中位生存时间 OMX 组6.0 h vs Vehicle 组4.7 h(P<0.003);总生存率 OMX 组85% vs Vehicle 组25%(P=0.004)。
证据类型、等级与局限
- 证据类型:动物实验(绵羊可控性失血性休克模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为 OMX 在绵羊可控性失血性休克模型中耐受良好,并改善代谢、血流动力学和生存结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Hemorrhagic shock is a major source of morbidity and mortality worldwide. While whole blood or blood product transfusion is a first-line treatment, maintaining robust supplies presents significant logistical challenges, particularly in austere environments. OMX is a novel nonhemoglobin (Hb)-based oxygen carrier derived from the H-NOX (heme-nitric oxide/oxygen binding) protein family. Because of their engineered oxygen (O 2 ) affinities, OMX proteins only deliver O 2 to severely hypoxic tissues. Additionally, unlike Hb-based oxygen carriers, OMX proteins do not scavenge nitric oxide in the vasculature. To determine the safety and efficacy of OMX in supporting tissue oxygen delivery and cardiovascular function in a large animal model of controlled hemorrhage, 2-3-week-old lambs were anesthetized, intubated, and mechanically ventilated. Hypovolemic shock was induced by acute hemorrhage to obtain a 50% reduction over 30 min. Vehicle (n = 16) or 400 mg/kg OMX (n = 13) treatment was administered over 15 min. Hemodynamics, arterial blood gases, and laboratory values were monitored throughout the 6-h study. Comparisons between groups were made using t tests, Wilcoxon rank sum test, and Fisher's exact test. Survival was assessed using Kaplan-Meier curves and the log-rank test. We found that OMX was well-tolerated and significantly improved lactate and base deficit trends, and hemodynamic indices ( P < 0.05). Median survival time was greater in the OMX-treated group (4.7 vs. 6.0 h, P < 0.003), and overall survival was significantly increased in the OMX-treated group (25% vs. 85%, P = 0.004). We conclude that OMX is well-tolerated and improves metabolic, hemodynamic, and survival outcomes in an ovine model of controlled hemorrhagic shock.
参考来源
- Maltepe E, Smith M, Boehme J, et al. OMX: A NOVEL OXYGEN DELIVERY BIOTHERAPEUTIC IMPROVES OUTCOMES IN AN OVINE MODEL OF CONTROLLED HEMORRHAGIC SHOCK. Shock. 2024. PMID: 38662597. doi:10.1097/SHK.0000000000002356
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。